MATERNAL HEALTH MEDICINES PIPELINE
The Accelerating Innovation for Mothers (AIM) project – spearheaded by the Concept Foundation and delivered in partnership with Policy Cures Research and Burnet Institute – was created with the aim of fostering greater investment in and development of critical maternal health medicines for five significant pregnancy-related conditions, where biomedical product gaps exist:
- Preterm labour/birth
- Preeclampsia/eclampsia
- Intrauterine growth restriction
- Postpartum haemorrhage
- Intrapartum foetal distress
As part of this work, Policy Cures Research created a current and historical landscape of medicines research and development (R&D) for these five conditions, which are included in the interactive product pipeline below. Alternatively, you can download the Excel version here as well as the report detailing the findings.
We have published several articles with insights provided by the database:
-
Analysis of a maternal health medicines pipeline database 2000–2021: New candidates for the prevention and treatment of fetal growth restriction in BJOG (February 2023)
-
Systematic evaluation of the pre-eclampsia drugs, dietary supplements and biologicals pipeline using target product profiles in BMC Medicine (November 2022)
- Target product profiles for novel medicines to prevent and treat preeclampsia: an expert consensus in PLOS Global Public Health (November 2022)
- Expert consensus on novel medicines to prevent preterm birth and manage preterm labour: target product profiles in BJOG (October 2022)
- Innovations in the prevention and treatment of postpartum hemorrhage: analysis of a novel medicines development pipeline database in the International Journal of Gynecology & Obstetrics (June 2022)